CymaBay Builds Seladelpar Case In PBC, But Door Not Closed On NASH

For the past year, CymaBay Therapeutics, Inc. has focused on developing its PPAR delta agonist seladapar in primary biliary cholangitis, as it looks to get past the roadblocks it faced in non-alcoholic steatohepatitis. The company is confident that it can take on Intercept Pharmaceuticals, Inc.’s lead in PBC with Ocaliva with seladepar’s better tolerability and benefit in cirrhotic patients – and a pooled analysis presented at the European Association for the Study of Liver meeting suggests it will have the data to do so.